AltraBio

Executive Summary

AltraBio is a French biotechnology company founded in 2019 that specializes in providing expert biological data analysis services using artificial intelligence (AI) and advanced statistics. The company helps clients—including pharmaceutical companies, university hospitals, and life sciences organizations—unlock insights from complex datasets such as cytometry, omics, and medical data. By positioning itself as an R&D partner, AltraBio addresses the growing need for sophisticated data interpretation in drug discovery and clinical research, particularly in the oncology and immunology fields. The company's AI-driven approach aims to accelerate decision-making and improve outcomes for its clients, though it operates in a competitive landscape of CROs and bioinformatics firms. As a private, early-stage company, AltraBio has not disclosed funding or valuation details, but its focus on AI-enhanced data analytics aligns with broader industry trends toward digitalization and precision medicine. The company's success will depend on its ability to secure partnerships, expand its service offerings, and differentiate itself from established players. Given its relatively recent founding and lack of public milestones, AltraBio represents an early-stage opportunity with potential but also significant uncertainty. Its conviction score reflects the limited available information and the need for further validation of its business model and market traction.

Upcoming Catalysts (preview)

• Q4 2026Announcement of a major pharma partnership40% success
• H1 2027Series A funding round closure60% success
• Q2 2027Launch of an AI-driven omics analysis platform50% success